EcoDrugPlus

Renin-Like

Ensembl ID : ENSSLDG00000006598
Gene Symbol: LOC111667152
3 Cross references
219 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSSLDG00000020309
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSSLDG00000023441
Gene Symbol: LOC111668805
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSSLDG00000013339
Gene Symbol: RARA
4 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSSLDG00000020820
Gene Symbol: RARB
4 Cross references
393 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSSLDG00000015867
Gene Symbol: LOC111644499
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSSLDG00000004204
Gene Symbol: RARG
3 Cross references
353 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSSLDG00000003597
Gene Symbol: LOC111667660
3 Cross references
377 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSSLDG00000021267
Gene Symbol: RXRA
3 Cross references
225 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSSLDG00000024081
Gene Symbol: LOC111673732
3 Cross references
223 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSSLDG00000012121
Gene Symbol: LOC111653387
3 Cross references
223 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSSLDG00000015238
Gene Symbol: LOC111656293
4 Cross references
223 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).